Cronos Group Inc
TSX:CRON
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.48
4.14
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cronos Group Inc
Cronos Group Inc
Cost of Revenue
Cronos Group Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cronos Group Inc
TSX:CRON
|
Cost of Revenue
-$85.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cost of Revenue
-$2.8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Cost of Revenue
-CA$689.3m
|
CAGR 3-Years
-137%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cost of Revenue
-CA$180.4m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-143%
|
CAGR 10-Years
N/A
|
|
|
C
|
Curaleaf Holdings Inc
CNSX:CURA
|
Cost of Revenue
-$1.3B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cronos Group Inc
Glance View
Cronos Group, Inc. engages in the production and distribution of cannabis. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-05-07. The firm is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones, Happy Dance and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivation Ltd, Cronos Israel G.S. Manufacturing Ltd., Cronos Israel G.S. Store Ltd. and Cronos Israel G.S. Pharmacy Ltd.
See Also
What is Cronos Group Inc's Cost of Revenue?
Cost of Revenue
-85.1m
USD
Based on the financial report for Jun 30, 2024, Cronos Group Inc's Cost of Revenue amounts to -85.1m USD.
What is Cronos Group Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-42%
Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for Cronos Group Inc have been 2% over the past three years , -42% over the past five years .
You don't have any saved screeners yet
